# Superluminal Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/superluminal-medicines

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.superluminalrx.com
- Total disclosed funding: $111M
- Latest round: Series B (Aug 10, 2026)
- Investors on record: 13

## About

Based in Massachusetts, US, and founded in 2022 by co-founders Cony D'Cruz and Ajay Yekkirala, Superluminal Medicines Inc. develops drugs using biotechnology, generative biology, and chemistry. In September 2026, Superluminal Medicines Inc. raised USD 60 million in series B funding led by BVF Partners, with participation from Deep Track Capital, Eli Lilly and Company, Perceptive Advisors, Catalio Capital Management, Gaingels , GC&H Investments, Insight Partners, NVIDIA Corporation, and RA Capital Management.


Superluminal Medicines Inc. offers a platform that improves the process of drug candidate identification. The company use deep biology and chemistry expertise, machine learning algorithms, and proprietary big data infrastructure to generate candidate-ready compounds with unprecedented speed and precision. The platform's predict-design-test architecture, which utilises accurate protein shape modelling and the design of highly selective compounds, enables the targeting of precise structural changes to achieve therapeutic effects.
 
The company plans to use the September 2026 funding to start a Phase 1 trial for its obesity treatment, advance other drug programs, and expand its drug discovery platform.

## Funding rounds

- Series B, Aug 10, 2026, $65M — Insight Partners, NVIDIA Corporation, Eli Lilly and Company, BVF Partners, RA Capital Management, GC&H Investments, Perceptive Advisors, Gaingels, Catalio Capital Management, Deep Track Capital
- Series A, Aug 21, 2024, $20M — Insight Partners, Cooley, Eli Lilly & Company, RA Capital Management, Gaingels, Catalio Capital Management, NVentures
- Seed, Mar 3, 2023, $26M — Insight Partners, NVIDIA Corporation, RA Capital Management, Gaingels

## Investors

- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Seed, Series A, Series B
- NVIDIA Corporation — Seed, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed, Series A, Series B
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed, Series A, Series B
- Cooley — Series A
- Eli Lilly & Company — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A, Series B
- NVentures — Series A
- Eli Lilly and Company — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- GC&H Investments (https://capitalatlas.ai/funds/gc-h-investments) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B